XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Stockholders’ Equity

 

9.Stockholders’ Equity

 

Preferred Stock

 

The Company has one series of preferred stock outstanding, known as the Series A Cumulative Perpetual Preferred Stock, par value $0.001 per share, with a $25.00 liquidation preference. As of March 31, 2022 and December 31, 2021, there were 1,319,156 and 1,252,299 shares of preferred stock issued and outstanding, respectively.

 

Common Stock

 

The Company has one class of common stock, par value $0.001. Each share of the Company’s common stock is entitled to one vote on all matters submitted to stockholders. As of March 31, 2022 and December 31, 2021, there were 14,004,172 and 13,754,206 shares of common stock issued and outstanding, respectively.

 

Dividends

 

Pursuant to the Certificate of Designations, Preferences and Rights of 9.0% Series A Cumulative Perpetual Preferred Stock of the Company, dividends, when, as and if declared by the Board of Directors, (or a duly authorized committee of the Board of Directors), will be payable monthly in arrears on the final day of each month, beginning August 31, 2021. During the three months ended March 31, 2022, the Board of Directors declared and paid the Company preferred stock dividend distributions of $749 thousand and for the fiscal year ended December 31, 2021, the Board of Directors declared and the Company paid monthly preferred stock dividends totaling an amount of approximately $630 thousand.

 

Reservation of Shares

 

The Company had reserved shares of common stock for future issuance as follows as of March 31, 2022:

 

         
Stock options outstanding     990,800  
Restricted stock units outstanding     555,847  
Warrants outstanding     2,692,355  
Common stock available for future equity awards or issuance of options     586,732  
Number of common shares reserved     4,825,734  

 

 

Income (Loss) per Share

 

The Company computes basic income (loss) per common share by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted income (loss) per share reflects the potential dilution, if any, computed by dividing income (loss) by the combination of dilutive common stock equivalents, comprised of shares issuable under outstanding investment rights, warrants and the Company’s stock-based compensation plans, and the weighted average number of shares of common stock outstanding during the reporting period. Dilutive common stock equivalents include the dilutive effect of in-the-money stock options, which are calculated based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of a stock option and the amount of compensation cost, if any, for future service that the Company has not yet recognized are assumed to be used to repurchase shares in the current period.

 

The Company notes as continuing operations was in a net loss position for the three months ended March 31, 2022 and 2021, as such basic and diluted Earnings-per-share (“EPS”) is the same amount as continuing operations acts as the control amount in which would cause antidilution. Not included in the computation of earnings per share, assuming dilution, for the three months ended March 31, 2022, were options to purchase 990,800 shares of the Company’s common stock, 555,847 nonvested restricted stock units, 2,692,355 outstanding warrants not exercised, and 1,479,908 shares of convertible notes outstanding. These potentially dilutive items were excluded because the calculation of incremental shares resulted in an anti-dilutive effect.

 

Not included in the computation of earnings per share, assuming dilution, for the three months ended March 31, 2021, were options to purchase 351,500 shares and 15,000 restricted stock units of the Company’s common stock. These potentially dilutive items were excluded because the Company incurred a loss during the period and their inclusion would be anti-dilutive.